Holen Sie sich die Stockscreener-App
238.37
1.09%
-2.63
Handel nachbörslich:
238.37
Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten
Axsome Therapeutics Inc (AXSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BlackRock, Inc. (AXSM) reports 2.74M Axsome Therapeutics shares in Schedule 13G/A - Stock Titan
Axsome Therapeutics Inc (AXSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Axsome Therapeutics, Inc. $AXSM Shares Sold by Orbimed Advisors LLC - MarketBeat
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
Caxton Associates LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
AXSM|Axsome Therapeutics Inc|Price:241.000|Chg%:-0.530 - TradingKey
Bank of New York Mellon Corp Cuts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc (AXSM) Income Statement - TradingKey
California Public Employees Retirement System Makes New Investment in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc. (AXSM) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc. (AXSM) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc. (AXSM) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc. (AXSM) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics Inc. (AXSM) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
Axsome Therapeutics Inc. (AXSM) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Axsome Therapeutics, Inc. (AXSM) stock price, news, quote and history - Yahoo Finance UK
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
First Trust Advisors LP Increases Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics, Inc. Revenue Breakdown – NASDAQ:AXSM - TradingView
Axsome Therapeutics Inc. (AXSM) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Axsome Therapeutics (AXSM) Stock is Attractive on the Back of its Key Drug - Yahoo Finance
Illinois Municipal Retirement Fund Invests $884,000 in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
68,453 Shares in Axsome Therapeutics, Inc. $AXSM Acquired by Hsbc Holdings PLC - MarketBeat
AXSOME THERAPEUTICS INC : LEERINK PARTNERS RAISES TARGET PRICE TO $265 FROM $250 - webull.com
AXSOME THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $310 - webull.com
Axsome Therapeutics (NASDAQ:AXSM) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) Upgraded to "Strong-Buy" at BMO Capital Markets - MarketBeat
AXSM Initiated Coverage by BMO Capital -- Outperform Rating Assi - GuruFocus
BMO Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310 - Moomoo
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
BMO Capital Initiates Axsome Therapeutics at Outperform With $310 Price Target - marketscreener.com
Fifth Third Bancorp Has $2.74 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
BMO Capital Initiates Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $310 - Moomoo
Axsome gains as narcolepsy therapy undergoes FDA review - MSN
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Axsome Therapeutics, Inc. $AXSM Stock Holdings Reduced by Principal Financial Group Inc. - MarketBeat
5 Best Biotech Stocks for 2026 and How to Invest - The Motley Fool
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Harmony Biosciences Holdings (HRMY) and Adlai Nortye Ltd. Sponsored ADR (ANL) - The Globe and Mail
Responsive Playbooks and the AXSM Inflection - Stock Traders Daily
H.C. Wainwright reiterates Axsome stock rating on FDA filing By Investing.com - Investing.com Nigeria
Axsome's NDA for AXS-12 in Narcolepsy Gets FDA Acceptance - Yahoo Finance
Jefferies Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $380 - Moomoo
H.C. Wainwright reiterates Axsome stock rating on FDA filing - Investing.com
H.C. Wainwright Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $290 - Moomoo
Is Axsome Therapeutics (AXSM) Reframing Its CNS Strategy With Pediatric Solriamfetol Trial Expansion? - webull.com
AXSM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $290 - GuruFocus
Axsome Therapeutics (AXSM) Wins FDA Acceptance For AXS 12 In Narcolepsy Cataplexy - simplywall.st
Axsome TherapeuticsFDA Does Not Plan Advis - Moomoo
Axsome gets FDA filing acceptance for narcolepsy drug AXS-12 By Investing.com - Investing.com Nigeria
Axsome Therapeutics' (AXSM) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):